10578 Science Center Drive
Suite 200
San Diego, CA 92121
United States
(858) 333-5280
https://www.contineum-tx.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 31
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Mr. Carmine N. Stengone MBA, MS | President, CEO, Secretary & Director | 790,3k | S.O. | 1976 |
Mr. Peter T. Slover CPA | Chief Financial Officer | 569,7k | S.O. | 1975 |
Dr. Daniel S. Lorrain Ph.D. | Chief Science Officer | 565,02k | S.O. | 1969 |
Dr. Stephen L. Huhn F.A.A.P, F.A.C.S., M.D. | Chief Medical Officer & Senior VP of Clinical Development | S.O. | S.O. | 1961 |
Mr. Austin Chen Ph.D. | SVP & Head of Research | S.O. | S.O. | S.O. |
Mr. Michael Mayberry | Senior Director & Corporate Controller | S.O. | S.O. | S.O. |
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.
L’ISS Governance QualityScore de Contineum Therapeutics, Inc. en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..